Why GeneDx Holdings Stock Just Dropped 16.6%
Key PointsGeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations.
On Tuesday, Nov. 10, the stock of biotech company GeneDx Holdings (WGS) experienced a significant decline of 16.6%, following the company reducing its growth projections for the year. This drop came amid broader market declines, with the S&P 500 and Nasdaq Composite falling by 0.4% and 0.7%, respectively.
GeneDx disclosed its Q3 results on Monday, after the market close. While sales increased by 5% to $123.1 million, aligning with market expectations, the company's testing volume fell short of forecasts. The firm reported a total of 32,134 exome and genome results, reflecting a 25% increase in volume, but it had anticipated a 29.2% or greater rise.
Management highlighted that certain initial paperwork was filtering out some lower-value orders, opting instead for higher-paying contracts. Consequently, GeneDx maintained its revenue forecast but reduced its volume growth target to a minimum of 28%. This adjustment underscores the pivotal role of expectations in stock market dynamics. Despite its continued growth, the company's performance did not meet the anticipated pace, leading to investor concerns about a potential third downward growth revision this year.
The company's experience serves as a cautionary tale in the stock market, illustrating how meeting expectations is crucial for investor confidence. For those seeking investment guidance, The Motley Fool's Stock Advisor service offers insights on the 10 best stocks to buy, supported by a remarkable average return of 852% compared to the S&P 500's 208% over the same period.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
